Efficacy of amorolfine nail lacquer for the prophylaxis of onychomycosis over 3 years

Journal of the European Academy of Dermatology and Venereology

Volumn 24, Issue 8, 2010, Pages 910-915

  Sigurgeirsson, B ^a   Olafsson, J H ^a   Steinsson, J T ^a   Kerrouche, N ^a   Sidou, F ^b  

^a Dermatology Center   (Iceland)

^b Galderma R and D   (France)

Author keywords

amorolfine; dermatophytes; matrix involvement; onychomycosis; prophylaxis

Indexed keywords

AMOROLFINE; TERBINAFINE;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; CLINICAL TRIAL; COLITIS; COLON PERFORATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROENTERITIS; HUMAN; INFLUENZA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MORPHOLOGY; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RECURRENT DISEASE; TOENAIL ONYCHOMYCOSIS; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ADULT; AGED; ANTIFUNGAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; FOOT DERMATOSES; HUMANS; LACQUER; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MORPHOLINES; NAPHTHALENES; ONYCHOMYCOSIS; PILOT PROJECTS; RECURRENCE; TREATMENT OUTCOME;

EID: 77954401379     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2009.03547.x     Document Type: Article

References (17)

1. Scher RK. Onychomycosis: Therapeutic update. J Am Acad Dermatol 1999 40 (6 Pt 2 S21 S26.
2. Andre J, Achten G. Onychomycosis. Int J Dermatol 1987 26 : 481 490.
3. Gupta AK, Jain HC, Lynde CW et al. Prevalence and epidemiology of unsuspected onychomycosis in subjects visiting dermatologists' offices in Ontario, Canada - a multicenter survey of 2001 subjects. Int J Dermatol 1997 36 : 783 787.
4. Sigurgeirsson B, Olafsson JH, Steinsson JB et al. Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. Arch Dermatol 2002 138 : 353 357.
5. Epstein E. How often does oral treatment of toenail onychomycosis produce a disease-free nail? Arch Dermatol 1998 134 : 1551 1554.
6. Haria M, Bryson HM. Amorolfine: a review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections. Drugs 1995 49 : 103 120.
7. Harman S, Ashbee HR, Evans EGV. Testing of antifungal combinations against yeast and dermatophytes. J Dermatol Treat. 2004 15 : 104 107.
8. Baran R, Feuilhade M, Datry A et al. A randomized trial of amorolfine 5% solution nail lacquer associated with oral terbinafine compared with terbinafine alone in the treatment of dermatophytic toenail onychomycosis affecting the matrix region. Br J Dermatol 2000 142 : 1177 1183.
9. Baran R, Sigurgeirsson B, de Berker D et al. A multicentre, randomized, controlled study of the efficacy,safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvement. Br J Dermatol 2007 157 : 149 157.
10. Mensing H, Polak-Wyss A, Splanemann V. Determination of the subungual antifungal activity of Amorolfine after 1 month's treatment in patients with oncychomycosis: comparison of two nail lacquer formulations. Clin Exp Dermatol 1992 17 (suppl 1 29 32.
11. Sigurgeirsson B, Olafsson JH, Steinsson JB et al. Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. Arch Dermatol 2002 138 : 353 357.
12. Tosti A, Piraccini BM, Stinchi C, Colombo MD. Relapses of onychomycosis after successful treatment with Systemic Antifungal: a three year Follow-Up. Dermatology 1998 197 : 162 166.
13. Crawford F, Hollis S. Topical treatments for fungal infections of the skin and nails of the foot. Cochrane Database of Syst Rev. 2007 3 : CD001434.
14. Scher RK, Tavakkol A, Sigurgeirsson B et al. Onychomycosis: diagnosis and definition of cure. J Am Acad Dermatol 2007 56 : 939 944.
15. Gupta AK, Lynch LE. Onychomycosis: review of recurrence rates, poor prognostic factors, and strategies to prevent disease recurrence. Cutis 2004 74 (Suppl 1 10 15.
16. Shuster S, Baran R. Recurrence of fungal nail disease and the dissociation of relapse from re-infection. Acta Derm Venereol 2001 81 : 154 155.
17. Scher RK, Baran R. Onychomycosis in clinical practice: factors contributing to recurrence. Br J Dermatol 2003 149 (Suppl 65 5 9.